To validate the impact of VEGFA signaling on SMAD3 expression levels, we differentiated AD and control derived iPSCs into pericytes79 and either activated or inhibited this signaling via recombinant VEGF or VEGFR2 inhibitor cocktail treatments, respectively. This evidence concerns the gene SMAD3 and Alzheimer disease.